Microsoft Word 02Preface doc

Particle Agglutination (PA) for HIV-1 was developed.    Because a study by KEMRI 
showed that there is only the HIV-1 strain in Kenya, the PA kit focused on only 
HIV-1, but not on HIV-2.    However, owing to the fact that it is a WHO requirement 
that HIV diagnostic kits should be able to detect both HIV-1 and HIV-2, KEMRI has 
started the development of a new blood test kit called KEMCOM, which is able to 
detect both HIV-1 and 2 at the same time. 
Besides the development of diagnostic kits, KEMRI has also implemented the 
screening of anti-viral medicinal plants and a cohort study for mother to child 
transmission in West Kenya (Kisumu, Busia).    The cohort study in Western Kenya 
was modified as a public health education activity and is continuing to be implemented 
in 2004. 
In addition, the TCTP mentioned above also included HIV/AIDS.